Phase 1b Study of Tizanidine in Pediatric Patients With Cerebral Palsy
Status:
Terminated
Trial end date:
2012-03-01
Target enrollment:
Participant gender:
Summary
A Single-Dose, Phase 1b, Multicenter, Open-Label Study to Assess the Pharmacokinetics, Safety
and Tolerability, and Pharmacodynamics of Tizanidine at 4 Different Oral Dose Levels in
Pediatric Subjects 2 to 16 Years Old With Mild to Moderate Spasticity Due to Cerebral Palsy.